Table 4. Type of Adjuvant Systemic Therapy in Patients With Hormone Receptor–Positive and Erb-B2 Receptor Tyrosine Kinase 2 (ERBB2)a–Negative Subtype by Type of Surgery in the Upfront Surgery Setting.
| Type of therapy | No. (%) | Difference (95% CI)b | |
|---|---|---|---|
| Arm A: ALND (n = 151) | Arm B: no ALND (n = 145) | ||
| Taxane-containing chemotherapy | 80 (53.0) | 72 (49.7) | 3.3% (−8.7% to 15%) |
| Anthracycline-containing chemotherapy | 78 (51.7) | 64 (44.1) | 7.5 (−4.5% to 20%) |
| Nontaxane/nonanthracycline–containing chemotherapy | 88 (58.3) | 76 (52.4) | 5.9% (−6.1% to 18%) |
| Carboplatin/cisplatin | 0 (0) | 3 (2.1) | −2.1% (−5.1% to 0.92%) |
| Aromatase inhibitors | 90 (59.6) | 89 (61.4) | −1.8% (−14% to 10%) |
| GnRH analogs | 17 (11.3) | 10 (6.9) | 4.4% (−2.8% to 12%) |
| Fulvestrant | 1 (0.7) | 2 (1.4) | −0.7 (−3.7% to 2.3%) |
| Tamoxifen | 30 (19.9) | 13 (9.0) | 11% (2.3% to 19%) |
| CDK4/6 inhibitors | 1 (0.7) | 3 (2.1) | −1.4 (−4.7% to 1.9%) |
Abbreviations: ALND, axillary lymph node dissection; CDK4/6, cyclin-dependent kinase 4/6; GnRH, gonadotropin-releasing hormone.
a
Formerly HER2 or HER2/neu.
b
Difference in proportions.